KR20230035597A - 호흡기 세포융합 바이러스 감염의 치료에 유용한 벤조디아제핀 유도체 - Google Patents
호흡기 세포융합 바이러스 감염의 치료에 유용한 벤조디아제핀 유도체 Download PDFInfo
- Publication number
- KR20230035597A KR20230035597A KR1020237003865A KR20237003865A KR20230035597A KR 20230035597 A KR20230035597 A KR 20230035597A KR 1020237003865 A KR1020237003865 A KR 1020237003865A KR 20237003865 A KR20237003865 A KR 20237003865A KR 20230035597 A KR20230035597 A KR 20230035597A
- Authority
- KR
- South Korea
- Prior art keywords
- dihydro
- phenyl
- oxo
- fluoro
- oxazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2010409.7A GB202010409D0 (en) | 2020-07-07 | 2020-07-07 | Pharmaceutical compounds |
| GB2010409.7 | 2020-07-07 | ||
| PCT/GB2021/051731 WO2022008911A1 (en) | 2020-07-07 | 2021-07-07 | Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230035597A true KR20230035597A (ko) | 2023-03-14 |
Family
ID=72050502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237003865A Pending KR20230035597A (ko) | 2020-07-07 | 2021-07-07 | 호흡기 세포융합 바이러스 감염의 치료에 유용한 벤조디아제핀 유도체 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230270751A1 (https=) |
| EP (1) | EP4178964A1 (https=) |
| JP (1) | JP7840923B2 (https=) |
| KR (1) | KR20230035597A (https=) |
| CN (1) | CN116075516B (https=) |
| BR (1) | BR112023000142A2 (https=) |
| CA (1) | CA3188752A1 (https=) |
| GB (1) | GB202010409D0 (https=) |
| MX (1) | MX2023000440A (https=) |
| WO (1) | WO2022008911A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201911944D0 (en) | 2019-08-20 | 2019-10-02 | Reviral Ltd | Pharmaceutical compounds |
| GB201915932D0 (en) | 2019-11-01 | 2019-12-18 | Reviral Ltd | Pharmaceutical compounds |
| GB202102602D0 (en) | 2021-02-24 | 2021-04-07 | Reviral Ltd | Pharmaceutical compounds |
| WO2024252355A1 (en) | 2023-06-08 | 2024-12-12 | Pfizer Inc. | Pediatric dosing regimens comprising a fusion inhibitor for the treatment of rsv |
| WO2025120500A1 (en) | 2023-12-06 | 2025-06-12 | Pfizer Inc. | Benzodiazepine compounds as n-protein inhibitors |
| WO2025153942A1 (en) | 2024-01-16 | 2025-07-24 | Pfizer Inc. | Benzodiazepine pyrazolo carboxamides as n-protein inhibitors |
| CN121621343A (zh) * | 2026-02-02 | 2026-03-10 | 云南大学 | 一种化合物在防控植物病原真菌尖孢镰刀菌上的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5127096B2 (ja) * | 1999-04-30 | 2013-01-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | アポトーシスにより誘導される自己免疫疾患を処置するためのベンゾジアゼピンの使用 |
| NZ538870A (en) | 2002-09-20 | 2007-04-27 | Arrow Therapeutics Ltd | Benzodiazepine derivatives and pharmaceutical compositions containing them |
| GB0406280D0 (en) | 2004-03-19 | 2004-04-21 | Arrow Therapeutics Ltd | Chemical compounds |
| WO2005090319A1 (en) | 2004-03-19 | 2005-09-29 | Arrow Therapeutics Limited | Process for preparing benzodiazepines |
| GB0406282D0 (en) * | 2004-03-19 | 2004-04-21 | Arrow Therapeutics Ltd | Therapeutic compounds |
| GB201506448D0 (en) | 2015-04-16 | 2015-06-03 | Univ Durham | An antimicrobial compound |
| DK3324977T3 (da) * | 2015-07-22 | 2022-10-17 | Enanta Pharm Inc | Benzodiazepinderivater som rsv-inhibitorer |
| GB201613942D0 (en) | 2016-08-15 | 2016-09-28 | Univ Of Durham The | An antimicrobial compound |
| US10398706B2 (en) * | 2017-01-06 | 2019-09-03 | Enanta Pharmaceuticals, Inc. | Heteroaryldiazepine derivatives as RSV inhibitors |
| WO2018226801A1 (en) | 2017-06-07 | 2018-12-13 | Enanta Pharmaceuticals, Inc. | Aryldiazepine derivatives as rsv inhibitors |
| KR101970214B1 (ko) * | 2017-07-17 | 2019-08-27 | 이화여자대학교 산학협력단 | 유기금속 화합물, 이들의 자기 조립체 및 이를 포함한 종양 진단 또는 치료용 조성물 |
| US10647711B2 (en) * | 2017-11-13 | 2020-05-12 | Enanta Pharmaceuticals, Inc. | Azepin-2-one derivatives as RSV inhibitors |
| WO2019204537A1 (en) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| GB201911944D0 (en) | 2019-08-20 | 2019-10-02 | Reviral Ltd | Pharmaceutical compounds |
| GB201915273D0 (en) | 2019-10-22 | 2019-12-04 | Reviral Ltd | Pharmaceutical compounds |
| GB201915932D0 (en) | 2019-11-01 | 2019-12-18 | Reviral Ltd | Pharmaceutical compounds |
| GB202010408D0 (en) | 2020-07-07 | 2020-08-19 | Reviral Ltd | Pharmaceutical compounds |
-
2020
- 2020-07-07 GB GBGB2010409.7A patent/GB202010409D0/en not_active Ceased
-
2021
- 2021-07-07 WO PCT/GB2021/051731 patent/WO2022008911A1/en not_active Ceased
- 2021-07-07 MX MX2023000440A patent/MX2023000440A/es unknown
- 2021-07-07 KR KR1020237003865A patent/KR20230035597A/ko active Pending
- 2021-07-07 EP EP21746095.5A patent/EP4178964A1/en active Pending
- 2021-07-07 JP JP2023501029A patent/JP7840923B2/ja active Active
- 2021-07-07 US US18/004,504 patent/US20230270751A1/en active Pending
- 2021-07-07 CN CN202180053511.8A patent/CN116075516B/zh active Active
- 2021-07-07 BR BR112023000142A patent/BR112023000142A2/pt unknown
- 2021-07-07 CA CA3188752A patent/CA3188752A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7840923B2 (ja) | 2026-04-06 |
| MX2023000440A (es) | 2023-04-13 |
| US20230270751A1 (en) | 2023-08-31 |
| CN116075516A (zh) | 2023-05-05 |
| EP4178964A1 (en) | 2023-05-17 |
| JP2023539985A (ja) | 2023-09-21 |
| BR112023000142A2 (pt) | 2023-01-31 |
| CN116075516B (zh) | 2026-02-03 |
| CA3188752A1 (en) | 2022-01-13 |
| GB202010409D0 (en) | 2020-08-19 |
| WO2022008911A1 (en) | 2022-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20230035597A (ko) | 호흡기 세포융합 바이러스 감염의 치료에 유용한 벤조디아제핀 유도체 | |
| US7473688B2 (en) | Indolobenzazepine HCV NS5B inhibitors | |
| AU2014358792C1 (en) | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | |
| CN105189511B (zh) | 人免疫缺陷病毒复制的抑制剂 | |
| US7547690B2 (en) | Compounds for the treatment of Hepatitis C | |
| KR102522832B1 (ko) | 호흡기 세포융합 바이러스 （ｒｓｖ）의 복제에 대하여 저해 활성을 갖는 피페리딘 치환된 피라졸로［１，５―ａ］피리미딘 유도체 | |
| US7521443B2 (en) | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | |
| EP4549438A1 (en) | Five-membered and six-membered nitrogen-containing compound, and intermediate, preparation method and use thereof | |
| JP7722981B2 (ja) | 医薬化合物 | |
| EP4129996A1 (en) | Novel aminopyrimidine egfr inhibitor | |
| EP3336084A1 (en) | 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors | |
| KR20230035596A (ko) | 호흡기 세포융합 바이러스 감염의 치료에 유용한 벤조디아제핀 유도체 | |
| WO2017100668A1 (en) | Inhibitors of bruton's tyrosine kinase and methods of their use | |
| US20200308145A1 (en) | Benzimidazole derivatives and their uses | |
| CA3158169A1 (en) | Benzodiazepine derivatives for treating a respiratory syncytial virus (rsv) infection | |
| CN112292374A (zh) | 一种新型磷酸肌醇3-激酶抑制剂及其制备方法和用途 | |
| EP4373817B1 (en) | Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer | |
| AU2021290208B2 (en) | Tricyclic compounds | |
| US8133884B2 (en) | Compounds for the treatment of hepatitis C | |
| JPWO2020116662A1 (ja) | シクロアルカン−１，３−ジアミン誘導体 | |
| KR20170094180A (ko) | 호흡기 세포융합 바이러스 （ｒｓｖ）의 복제에 대하여 저해 활성을 갖는 피페리딘 치환된 삼환식 피라졸로［１，５―ａ］피리미딘 유도체 | |
| RU2840815C2 (ru) | Фармацевтические соединения | |
| HK40094055A (zh) | 可用於治疗呼吸道合胞病毒感染的苯二氮杂䓬衍生物 | |
| TW202426442A (zh) | 活化ampk之化合物 | |
| HK1230202B (en) | Inhibitors of lysine specific demethylase-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |